



Attorney Docket No. 26418U

885

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

CAHILL et al.

Group Art Unit: 1614

Serial No. 10/511,205

Examiner: Unknown

Filed: February 15, 2005

For: **USE OF SUBSTANCES FOR TREATING TUMORS**

TRANSMITTAL LETTER

Commissioner of Patents
P.O. Box 1450
Alexandria, Va 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Information Disclosure Statement;
- (3) PTO Form 1449 citing 19 references;
- (4) Copies of 19 references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By:

Gary M. Nath
Registration No. 26,965
Tanya E. Harkins
Registration No. 52,993
Customer No. 20529

Date: May 19, 2005

NATH & ASSOCIATES PLLC
1030 15th Street NW - 6th Floor
Washington, D.C. 20005
GMN/TEH/ng/:IDS_TR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

CAHILL et al.

Serial No. 10/511,205

Filed: February 15, 2005

Group Art Unit: 1614

Examiner: Unknown

For: USE OF SUBSTANCES FOR TREATING TUMORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
 ii. a check in the amount required by 37 C.F.R. § 1.17(p).

c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.

Certification report(e) below; and

a check in the amount as required by § 1.17(p).

d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]



- [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or
- [] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
or
- [] Appropriate certification is attached.

[X] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[X] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or


[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:


Gary M. Nath
Registration No. 26,965
Tanya E. Harkins
Registration No. 52,993
Customer No. 20529

Date: May 19, 2005

NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005
Tel. (202) 775-8383
Fax. (202) 775-8396
GMN/TRH/nra (TDSstatement GMN)

O I P E

MAY 19 2005

FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAtty Docket
26418USerial No.
10/511,205Applicant
CAHILL et al.Filing Date
February 15, 2005Group Art Unit
1614OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA	Bukkapatnam, R. et al. "Radical Prostatectomy in the Management of Clinically Localized Prostate Cancer", <u>Cancer Control</u> , vol.8(6) pp.496-502, 2001.
AB	Waghray, A. et al. "Identification of Differentially Expressed Genes by Serial Analysis of Gene Expression in Human Prostate Cancer", <u>CANCER RESEARCH</u> , vol. 61 pp.4283-4286, 2001.
AC	Magee, J.A. et al. "Expression Profiling Reveals Hepsin Overexpression in Prostate Cancer", <u>CANCER RESEARCH</u> , vol.61 pp.5692-5696, 2001.
AD	Welsh, J.B. et al. "Analysis of Gene Expression Identifies Candidate Markers and Pharmacological Targets in Prostate Cancer", <u>CANCER RESEARCH</u> , vol.61 pp.5974-5978, 2001.
AE	Rini, B.I. et al. "Immunotherapy for Prostate Cancer", <u>Current Oncology Reports</u> , vol.3 pp.418-423, 2001.
AF	Heidenreich, A. et al. "Current Status of Cytotoxic Chemotherapy in Hormone Refractory Prostate Cancer", <u>Eur Urol</u> , vol. 39 pp.121-130, 2001.
AG	Eder, I.E. et al. "Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic", <u>Eur Urol</u> , vol.40 pp.241-251, 2001.
AH	Miyake, H. et al. "Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes unregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity", <u>International Journal of Urology</u> , vol.8 pp.337-349, 2001.
AI	Afrin, L.B. et al. "Medical Therapy of Prostate Cancer: 1999", <u>The Journal of the South Carolina Medical Association</u> , vol.96 pp.77-84, 2000.
AJ	Stamey, T.A. et al. "Molecular Genetic Profiling of Gleason Grade 4/5 Prostate Cancers Compared to Benign Prostatic Hyperplasia", <u>The Journal of Urology</u> , vol.166 pp.2171-2177, 2001.
AK	Pentyala, S.N. et al. "Prostate Cancer: a comprehensive review", <u>Medical Oncology</u> , vol.17 pp.85-105, 2000.
AL	Dhanasekaran, S.M. et al. "Delineation of prognostic biomarkers in prostate cancer", <u>NATURE</u> , vol.412 pp.822-826, 2001.
AM	Chaib, H. et al. "Profiling and Verification of Gene Expression Patterns in Normal and Malignant Human Prostate Tissues by cDNA Microarray Analysis", <u>Neoplasia</u> , vol. 3(1) pp.43-52, 2001.
AN	DiPaola, R.S. et al. "State-of-the-Art Prostate Cancer Treatment and Research- A Report from The Cancer Institute of New Jersey", <u>New Jersey Medicine</u> , vol.98 pp.23-33, 2001.
AO	Auclerc, G. et al. "Management of Advanced Prostate Cancer", <u>The Oncologist</u> , vol.5 pp.36-44, 2000.
AP	Hussain, A. et al. "Management of Advanced/Metastatic Prostate Cancer: 2000 Update", <u>Oncology</u> , vol.14(12), 2000.
AQ	Chetcuti, A. et al. "Identification of Differentially Expressed Genes in Organ-Confining Prostate Cancer by Gene Expression Array", <u>The Prostate</u> , vol.47 pp.132-140, 2001.
AR	Crawford, E.D. et al. "Overview: Hormone Refractory Prostate Cancer", <u>Urology</u> , vol.54 pp.1-7, 1999.
AS	Bartsch, G. et al. "Prostate Cancer Mortality After Introduction of Prostate-Specific Antigen Mass Screening in the Federal State of Tyrol, Austria", <u>Urology</u> , vol.58(3) pp.417-424, 2001.

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.